Tradestie Institutional Equity Comparison Engine
MYGN vs NDRA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
MYGN Overall Edge
MYGN Captures Institutional Edge (3โ1 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Myriad Genetics Inc (MYGN) driven by superior Valuation, Momentum & Technical, Options & Structure while NDRA counters with relative strength in Growth & Margin. Fundamentally, MYGN trades at 54.0x Forward P/E with -13.3% operating margin (-1.5% YoY revenue) versus NDRA at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, MYGN sits in SURGE (22nd %ile IV; Dealer Gamma Walls on Pro) against NDRA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
MYGN
MYGN 54.0x vs NDRA N/M Fwd P/E
Growth & Margin Winner
NDRA
Op Margin -13.3% vs 0.0% ยท YoY -1.5% vs +0.0%
Momentum & Technical Winner
MYGN
1Y -12.3% vs -32.7% ยท 52W Pos 53% vs 37%
Options & Structure Winner
MYGN
SURGE (22nd %ile IV) vs UNCLASSIFIED (N/A IV)
MYGN
NASDAQ
Myriad Genetics Inc
In Vitro & In Vivo Diagnostic Substances
$5.57
-1.59% 1D
Market Cap
$542.9M
1M Return
+39.95%
1Y Return
-12.28%
Forward P/E
54.0x
Unified AI Score
46.3 / 100
HOLD
Tech 30.0
Fund 44.0
Flow 56.0
Mom 50.0
NDRA
NASDAQ
ENDRA Life Sciences Inc. Common Stock
Electromedical & Electrotherapeutic Apparatus
$4.42
+0.23% 1D
Market Cap
$6.6M
1M Return
-6.75%
1Y Return
-32.72%
Forward P/E
N/M
Unified AI Score
44.7 / 100
HOLD
Tech 35.0
Fund 46.0
Flow 50.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
MYGN -12.28%
NDRA -32.72%
Spread: +20.44 pp (MYGN Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | MYGN Revenue | NDRA Revenue | MYGN Op. Margin | NDRA Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $740M | $0M | 16.4% | -146080.5% | MYGN |
| FY2019 | $850M | N/A | 0.9% | N/A | MYGN |
| FY2020 | $560M | N/A | -52.0% | N/A | MYGN |
| FY2021 | $690M | N/A | -27.6% | N/A | MYGN |
| FY2022 | $680M | N/A | -20.7% | N/A | MYGN |
| FY2023 | $750M | N/A | -34.2% | N/A | MYGN |
| FY2024 | $840M | N/A | -14.7% | N/A | MYGN |
| FY2025 | $820M | N/A | -47.0% | N/A | MYGN |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | MYGN | NDRA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $542.9M | $6.6M | Larger Scale | MYGN |
| Trailing P/E Ratio Valuation | 54.0x | N/M | Lower Multiple | MYGN |
| Forward P/E Ratio Valuation | 54.0x | N/M | Lower Multiple | MYGN |
| Revenue Growth (YoY) Growth | -1.5% | +0.0% | Higher Growth | NDRA |
| Operating Margin (TTM) Profitability | -13.3% | 0.0% | Higher Margin | NDRA |
| Net Profit Margin Profitability | -16.1% | 0.0% | Higher Margin | NDRA |
| Return on Equity (ROE) Capital Efficiency | -40.2% | -152.0% | Higher ROE | MYGN |
| 52-Week Range Position Momentum | 53% ($3โ$8) | 37% ($3โ$7) | Stronger Trend | MYGN |
| Beta / 30D Volatility Risk Regime | 0.68ฮฒ ยท 122% Vol | 0.71ฮฒ ยท 48% Vol | Lower Realized Risk | NDRA |
| Unified Institutional Score Composite Signal | 46.3 / 100 (HOLD) | 44.7 / 100 (HOLD) | Higher Composite | MYGN |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full MYGN vs NDRA Buy Guide
MYGN
SURGE
12d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
22nd %ile
IV Regime
Compressed (<25th %ile)
NDRA
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither MYGN nor NDRA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.